[go: up one dir, main page]

KR910019638A - Tgf-베타 조성물 - Google Patents

Tgf-베타 조성물 Download PDF

Info

Publication number
KR910019638A
KR910019638A KR1019910008175A KR910008175A KR910019638A KR 910019638 A KR910019638 A KR 910019638A KR 1019910008175 A KR1019910008175 A KR 1019910008175A KR 910008175 A KR910008175 A KR 910008175A KR 910019638 A KR910019638 A KR 910019638A
Authority
KR
South Korea
Prior art keywords
acid
composition
tgf
pufa
retinoid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1019910008175A
Other languages
English (en)
Inventor
제임스 뉴만 마이클
Original Assignee
장-자크 오게이, 롤란드 보러
에프. 호프만-라 룻슈 아크티엔게젤샤프트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 장-자크 오게이, 롤란드 보러, 에프. 호프만-라 룻슈 아크티엔게젤샤프트 filed Critical 장-자크 오게이, 롤란드 보러
Publication of KR910019638A publication Critical patent/KR910019638A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

내용 없음

Description

TGF-베타 조성물
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 TGF-β1의 존재 및 부재하에 10%송아지 혈청 함유 배지 및 혈청 비함유 배지중에서 A549 세포의 앵커리지-의존성(anchorage-dependent)성장을 나타낸다. 세포들은 200pM TFG-β1이 있거나(▲)없는 (△)혈청 비함유 배지 또는 100pMTGF-β1이 있거나 (●)또는 (○)10%송아지 태아혈청 함유 RPMl 1640배지중에서 성장시킨다. 제2도는 TGF-β1에 의한 A549세포 성장 억제에 대한 지방산의 효과를 나타낸다. 세포들을 나타낸 지방산을 함유한 혈청 비함유 조건하에서 200pM TGF-β1의 존재 (●)또는 (○)중에서 성장시킨다. 세포수는 TGF-β1을 첨가한지 5일 후에 측정한다. 세포수는 TGF-β1에 의한 A549세포 성장의 PUFA의 존성 억제는 12번의 독립적인 실험에서 관측했다. 제3도는 리놀레산의 존재 및 부재하에서 TFG-β1에 의한 A549세포 억제의 투여량 반응 커브를 나타낸다. 세포들을 2μg/mg의 리놀레산 존재 (●)또는 부재 (○)하에서 나타낸 농도의 TGF-β1을 갖는 혈청 비함유 조건에서 성장시킨다. 세포수는 TGF-β1을 첨가한지 5일 후에 측정한다.

Claims (16)

  1. 형질전환 발육인자-β1(TGF-β1) 및 고도불포화 지방산(PUFA)및/또는 그의 유도체를 포함하는 조성물.
  2. 제1항에 있어서, 상기 TGF-β1이 재조합 인간 TGF-β1인 조성물.
  3. 제1항 또는 제2항에 있어서, 상기 PUFA가 2개 이상의 이중결합을 갖는 조성물.
  4. 제1항 내지 제3항중 어느 한 항에 있어서, 상기 PUFA가 리놀레산, 알파-리놀렌산, 감마-리놀렌산, 아리키돈산, 디호모감마-리놀렌산, 에이코사펜타에노산 및/또는 도코사헥사에산 또는 고도불포화 지방산을 함유한 조직 추출물인 조성물.
  5. 제1항 내지 제4항중 어느 한 항에 있어서, 레티노이드를 또한 함유하는 조성물.
  6. 제5항에 잇어서, 상기 레티노이드가 레티노산인 조성물.
  7. 약제로 사용하기 위한 제1항내지 제6항중 어느 한항의 조성물.
  8. 종양 질환 치료에 사용하기 위한 제1항 내지 제6항중 어느 한항에 청구된 바와 같은 조성물.
  9. 제1항 내지 제6항중 어느 한한에 청구된 바와 같은 조성물 효과량과 약학제제에 통상적으로 사용되는 하나이상의 불활성 무독성의, 치료학적으로 허용되는 담체 물질을 함유하는 약학 제제.
  10. TGF-β1,PUFA 및/또는 그의 유도체, 임의로 레티노이드와 하나 이상의 불활성, 무독성의 치료학적으로 허용되는 담체를 포함하는 동시 투여, 별도 투여 또는 연속 투여하기 위한 제제형태의 종양 질환의 치료에 사용하기 위한 생성물.
  11. 제10항에 있어서, 상기 TGF-β1이 재조합 인간 TGF-β1인 생성물.
  12. 제10항 또는 제11항에 있어서, 상기 PUFA가 2개 이상의 이중결합을 갖는 생성물.
  13. 제10항 내지 제12항중 어느 한항에 있어서, 상기 PUFA가 리놀레산, 알파-리놀렌산, 감마-리놀렌산, 아라키돈산, 디호모감마-리놀렌산, 에이코사펜타에노산 및/또는 도코사헥사에노산 또는 고도불포화 지방산을 함유한 조직 추출물로부터 선택된 생성물.
  14. 유효량의 TGF-β1을 PUFA또는 그의 유도체와 함께 동시 투여, 별도 투여 또는 연속 투여함을 포함하는, 종양질환, 특히 암 및 흑생종을 치료하는 방법.
  15. 제14항에 있어서, 상기 치료가 또한 효과량의 레티노이드를 투여함을 포함하는 방법.
  16. 본 명세서, 특히 실시예에 기재된 바와 실질적으로 같은 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개되는 것임.
KR1019910008175A 1990-05-22 1991-05-20 Tgf-베타 조성물 Withdrawn KR910019638A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US527,215 1990-05-22
US07/527,215 US5147854A (en) 1990-05-22 1990-05-22 Tgf-b compositions and method

Publications (1)

Publication Number Publication Date
KR910019638A true KR910019638A (ko) 1991-12-19

Family

ID=24100576

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019910008175A Withdrawn KR910019638A (ko) 1990-05-22 1991-05-20 Tgf-베타 조성물

Country Status (16)

Country Link
US (1) US5147854A (ko)
EP (1) EP0462398A1 (ko)
JP (1) JPH05213772A (ko)
KR (1) KR910019638A (ko)
AU (1) AU636489B2 (ko)
CA (1) CA2042973A1 (ko)
FI (1) FI912462A7 (ko)
HU (1) HUT57599A (ko)
IE (1) IE911736A1 (ko)
IL (1) IL98177A0 (ko)
MC (1) MC2259A1 (ko)
NO (1) NO911949L (ko)
NZ (1) NZ238179A (ko)
PT (1) PT97728A (ko)
YU (1) YU89891A (ko)
ZA (1) ZA913647B (ko)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5248666A (en) * 1984-03-23 1993-09-28 Oncogen Methods for inhibiting neoplastic cell proliferation using platelet factor 4
US4890152A (en) * 1986-02-14 1989-12-26 Matsushita Electric Works, Ltd. Plastic molded chip carrier package and method of fabricating the same
US5824297A (en) * 1990-06-25 1998-10-20 Oncogene Science, Inc. Tissue-derived tumor growth inhibitors, methods of preparation and uses thereof
GB9106678D0 (en) * 1991-03-28 1991-05-15 Ferguson Mark W J Wound healing
US5817625A (en) * 1992-09-21 1998-10-06 Oncogene Science, Inc. Methods of prevention of oral mucositis with transforming growth factor beta
US5726058A (en) * 1992-12-01 1998-03-10 Jalkanen; Markku Syndecan stimulation of cellular differentiation
EP0671909B1 (en) * 1992-12-01 2000-12-27 Oy Biotie Therapies Syndecan stimulation of cellular differentiation
DE4304394A1 (en) * 1993-02-13 1993-09-02 Fresenius Ag Prepn. for nourishment of oncological patients - comprises fats formulation contg. oleic acid, alpha-linolenic acid, etc., and opt. carbohydrate and proteins
RU2246315C2 (ru) * 1993-08-10 2005-02-20 Биофарм Гезелльшафт Цур Биотехнологишен Энтвиклунг Фон Фармака Мбх НОВЫЙ ФАКТОР РОСТА/ДИФФЕРЕНЦИАЦИИ TGF-β-СЕМЕЙСТВА И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ
RU2157406C2 (ru) * 1993-08-10 2000-10-10 Биофарм Гезелльшафт Цур Биотехнологишен Энтвиклунг Фон Фармака Мбх НОВЫЙ ФАКТОР РОСТА/ДИФФЕРЕНЦИАЦИИ TGF-β-СЕМЕЙСТВА
US6017727A (en) * 1994-03-07 2000-01-25 Biotie Therapies Ltd. Syndecan enhancer element and syndecan stimulation of cellular differentiation
US6077828A (en) 1996-04-25 2000-06-20 Abbott Laboratories Method for the prevention and treatment of cachexia and anorexia
WO1998004680A1 (en) * 1996-07-26 1998-02-05 University Of Manitoba Serum-free medium for growth of anchorage-dependant mammalian cells
DE19646392A1 (de) * 1996-11-11 1998-05-14 Lohmann Therapie Syst Lts Zubereitung zur Anwendung in der Mundhöhle mit einer an der Schleimhaut haftklebenden, Pharmazeutika oder Kosmetika zur dosierten Abgabe enthaltenden Schicht
US20020141995A1 (en) * 1997-06-10 2002-10-03 Irvin Charles G. Method for treatment of inflammatory disease
US6248723B1 (en) 1997-06-10 2001-06-19 National Jewish Medical And Research Center Method for treatment of inflammatory disease
US5891925A (en) * 1997-06-27 1999-04-06 Abbott Laboratories Diagnostic method for assessing the serum cholesterol response to low diets
WO2001024812A1 (en) * 1999-10-06 2001-04-12 N.V. Nutricia USE OF TRANSFORMING GROWTH FACTOR β AND GROWTH FACTORS IN THE TREATMENT AND PREVENTION OF DISEASES OF THE INTESTINAL MUCOSA
US6767541B2 (en) * 2000-03-20 2004-07-27 The Regents Of The University Of California HER-2/neu overexpression abrogates growth inhibitory pathways
US6689810B2 (en) * 2001-08-21 2004-02-10 Cellular Sciences, Inc. Method for treating pulmonary disease states in mammals by altering indigenous in vivo levels of nitric oxide
US20040229791A1 (en) * 2002-12-31 2004-11-18 Jung San Huang Compositions and methods of modulating TGF-beta activity by fatty acids
CA2436650A1 (en) * 2003-08-06 2005-02-06 Naturia Inc. Conjugated linolenic acid (clnatm) compositions: synthesis, purification and uses
US20060186078A1 (en) * 2005-02-22 2006-08-24 David Ziegenhorn Screw on dispensing closure with structure for preventing removal
ES2264886B1 (es) * 2005-05-12 2008-02-01 Proyecto Empresarial Brudy, S.L. Utilizacion de acido docosahexaenoico para el tratamiento de enfermedades tumorales.
GB0704678D0 (en) 2007-03-09 2007-04-18 Univ Bristol Pro- and anti-angiogenic treatments
CA2699454C (en) * 2007-08-27 2012-07-24 Auxagen, Inc. Methods for inhibiting tgf-.beta.
US20110189315A1 (en) * 2008-06-10 2011-08-04 Regina Goralczyk Plant extract and pufa combinations
WO2010033507A1 (en) * 2008-09-16 2010-03-25 St. Louis University Method of enhancing tgf-beta signalling
WO2014130411A1 (en) * 2013-02-22 2014-08-28 Emory University Tgf-beta enhancing compositions for cartilage repair and methods related thereto

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4326055A (en) * 1977-12-22 1982-04-20 Hoffmann-La Roche Inc. Stilbene derivatives
CA1275922C (en) * 1985-11-28 1990-11-06 Harunobu Amagase Treatment of cancer
US4929442A (en) * 1986-09-26 1990-05-29 Exovir, Inc. Compositions suitable for human topical application including a growth factor and/or related materials
US4816442A (en) * 1986-11-07 1989-03-28 Collagen Corporation Method of inhibiting tumor growth sensitive to CIF-βtreatment

Also Published As

Publication number Publication date
FI912462L (fi) 1991-11-23
PT97728A (pt) 1992-02-28
CA2042973A1 (en) 1991-11-23
HU911672D0 (en) 1991-11-28
AU7713991A (en) 1991-12-12
AU636489B2 (en) 1993-04-29
FI912462A7 (fi) 1991-11-23
ZA913647B (en) 1992-02-26
JPH05213772A (ja) 1993-08-24
YU89891A (sh) 1994-06-10
FI912462A0 (fi) 1991-05-21
MC2259A1 (fr) 1993-04-26
NO911949D0 (no) 1991-05-21
NZ238179A (en) 1993-04-28
IL98177A0 (en) 1992-06-21
HUT57599A (en) 1991-12-30
EP0462398A1 (en) 1991-12-27
IE911736A1 (en) 1991-12-04
US5147854A (en) 1992-09-15
NO911949L (no) 1991-11-25

Similar Documents

Publication Publication Date Title
KR910019638A (ko) Tgf-베타 조성물
US5888541A (en) Fatty acid treatment
CA2033823C (en) Combination of gla or dgla and selenium in psychiatric disorder treatment
US5618558A (en) Fatty acid treatment
AU618814B2 (en) Essential fatty acid compositions
AU677275B2 (en) Formulation for use in smokers
CA1302266C (en) Formulations containing unsaturated fatty acids for the synthesis of prostaglandins and hydroxy-fatty acids in biological systems
CA1310911C (en) Essential fatty acid compositions
EP0460848A1 (en) Stearidonic acid and/or eicosatetraenoic acid for the treatment of inflammations
IE59445B1 (en) Use of gamma-linolenic acid and related compounds for the manufacture of a medicament for the treatment of complications of diabetes mellitus
US5246726A (en) Iron-containing composition and method for treatment of cancer
EG17609A (en) Process for preparation of therapeutic agents from derivatives of propoimic acid.
CA1287297C (en) Iron - containing compositions and method for treatment of cancer
AU633618B2 (en) Fatty acid therapy
ATE179889T1 (de) Arzneimittel, die ester omega-3 polyungesättigter säuren enthalten und deren verwendung in der topischen behandlung morbider erkrankungen
WO1998016215A1 (en) Use of essential fatty acids for the treatment and prevention of radiation damage to erythrocytes
Das et al. Psoriasis: current concepts and new approaches to therapy
JPS6216415A (ja) 月経前症候群治療用医薬組成物およびその治療方法
JPH0399011A (ja) 医薬組成物
AU604226B2 (en) Method of modifying the lipid structure function and expression of cell membranes and pharmaceutical compositions for use therein
Riku et al. Growth inhibitory effect of eicosapentaenoic acid on cultured human epidermal keratinocytes
CA2003261A1 (en) Process for preparing melanogenic inhibitor, and pigmentation-lightening agent containing the same

Legal Events

Date Code Title Description
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 19910520

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid